ArticleCirculation reports2026
Optimizing Diagnosis of Transthyretin Amyloidosis Cardiomyopathy in Japan: Care Pathway Barriers and Opportunities.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, underdiagnosed cause of heart failure, particularly among older adults. Despite updated Japanese Circulation Society (JCS) guidelines and advances in imaging and therapies, diagnostic delays and variability persist. Understanding real-world barriers is essential for improving patient outcomes. Methods and Results: A mixed-methods approach was used to develop an evidenced care pathway for ATTR-CM in Japan. A literature review of guidelines and epidemiological data informed a draft pathway. Semistructured interviews with 5 cardiologists from JCS-certified and regional hospitals explored perceived deviations from guidelines and barriers to care. Thematic analysis highlighted 5 perceived challenges: variability in physician awareness, particularly outside heart failure subspecialties; the influence of symptom type and entry point on diagnostic delay; fragmented referral pathways; low patient awareness and disengagement due to complex processes; and limited access to and interpretation of diagnostic tests. Conclusions: Removal of the tissue biopsy requirement for diagnosis and treatment prescription is an important step towards less invasive care and broader treatment access. However, challenges remain in ensuring that non-invasive diagnostic methods are widely available and correctly interpreted. The exploratory findings reported here suggest that addressing awareness gaps, referral fragmentation, and variations in diagnostic expertise may help realize the benefits of non-biopsy diagnosis in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.